On April 30, 2026, Colossal Biosciences announced the bluebuck (Hippotragus leucophaeus) as the sixth species in its de-extinction portfolio, adding the first antelope and first African megafauna to a program that already included woolly mammoth, dire wolf, thylacine, dodo, and moa. The company said the bluebuck project has been underway since 2024 and is supported by local South African conservation organizations, with work focused on antelope reproduction and stem-cell science.
Technically, the significance is not the bluebuck itself but the capability stack: large-fragment DNA replacement, engineered cell lines, assisted reproductive technologies for antelopes, and eventual somatic cell nuclear transfer using surrogate mothers. For the Ark, those methods map directly onto high-value preservation tools: frozen biobanks, genomic restoration of endangered species, controlled breeding under constrained conditions, and embryo transfer workflows that could support food-web reconstruction in closed lunar ecosystems.
Ark priorities are to track whether Colossal’s antelope platform produces reproducible advances in genome editing, stem-cell derivation, and surrogate gestation across bovids, especially if these methods become transferable to other mammalian conservation targets. The team should monitor any published protocols, success rates, and failure modes from the bluebuck effort, and evaluate whether similar biobanking and reproductive pipelines should be incorporated into the Ark’s long-horizon biodiversity archive.